PMID- 34357559 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210910 IS - 1869-6953 (Print) IS - 1869-6961 (Electronic) IS - 1869-6961 (Linking) VI - 12 IP - 9 DP - 2021 Sep TI - The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus. PG - 2499-2515 LID - 10.1007/s13300-021-01125-8 [doi] AB - INTRODUCTION: Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with type 2 diabetes mellitus (T2DM). METHODS: This is the prespecified subanalysis study of the "Using TOfogliflozin for Possible better Intervention against Atherosclerosis for type 2 diabetes patients (UTOPIA)" trial. Treatment-related QOL was evaluated at baseline, week 26, week 52, and week 104 after the initiation of the study using the Diabetes Therapy-Related QOL questionnaire (DTR-QOL). Among the 340 patients in the original UTOPIA study, a total of 252 patients (127, tofogliflozin group; 125, conventional treatment group) who completed the DTR-QOL questionnaire at baseline were the study subjects of the current subanalysis. RESULTS: The tofogliflozin and conventional treatment groups exhibited almost comparable baseline clinical characteristics, while the use of antihypertensive drugs and lipid-lowering agents was significantly lower in the tofogliflozin treatment group than in the conventional treatment group. Tofogliflozin treatment increased the total score of DTR-QOL7 from baseline (P < 0.001), while conventional treatment did not change it. There were statistically significant differences in delta change in the total DTR-QOL7 score and DTR-QOL7 Q4, Q5, Q6, and Q7 scores from the baseline to week 104 between the treatment groups. Delta changes in HbA1c (Spearman's correlation coefficient, rho = - 0.30, P < 0.001), fasting blood glucose (rho = - 0.16, P = 0.031), BMI (rho = - 0.19, P = 0.008), and waist circumference (rho = - 0.17, P = 0.024) at week 104 were negatively associated with delta change in the total QOL7 score. CONCLUSIONS: Our data indicated that tofogliflozin treatment improved treatment-related QOL compared to conventional treatment in Japanese patients with T2DM, in accordance with the improvement of major cardiovascular risk factors. TRIAL REGISTRATION: UMIN000017607. CI - (c) 2021. The Author(s). FAU - Katakami, Naoto AU - Katakami N AUID- ORCID: 0000-0001-9020-8320 AD - Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan. katakami@endmet.med.osaka-u.ac.jp. AD - Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan. katakami@endmet.med.osaka-u.ac.jp. FAU - Mita, Tomoya AU - Mita T AD - Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo, 113-8421, Japan. FAU - Yoshii, Hidenori AU - Yoshii H AD - Department of Medicine, Diabetology and Endocrinology, Juntendo Tokyo Koto Geriatric Medical Center, Koto-ku, Tokyo, 136-0075, Japan. FAU - Shiraiwa, Toshihiko AU - Shiraiwa T AD - Shiraiwa Medical Clinic, 4-10-24 Hozenji, Kashiwara, Osaka, 582-0005, Japan. FAU - Yasuda, Tetsuyuki AU - Yasuda T AD - Department of Diabetes and Endocrinology, Osaka Police Hospital, 10-31, Kitayama-cho, Tennoji-ku, Osaka, 543-0035, Japan. FAU - Okada, Yosuke AU - Okada Y AD - First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. FAU - Torimoto, Keiichi AU - Torimoto K AD - First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. FAU - Umayahara, Yutaka AU - Umayahara Y AD - Department of Diabetes and Endocrinology, Osaka General Medical Center, 3-1-56, Bandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan. FAU - Kaneto, Hideaki AU - Kaneto H AD - Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan. FAU - Osonoi, Takeshi AU - Osonoi T AD - Nakakinen Clinic, 745-5, Nakadai, Naka, Ibaraki, 311-0113, Japan. FAU - Yamamoto, Tsunehiko AU - Yamamoto T AD - Diabetes and Endocrinology, Kansai Rosai Hospital, 3-1-69, Inabaso, Amagasaki, Hyogo, Japan. FAU - Kuribayashi, Nobuichi AU - Kuribayashi N AD - Misaki Naika Clinic, 6-44-9, Futawa-higashi, Funabashi, Chiba, 274-0805, Japan. FAU - Maeda, Kazuhisa AU - Maeda K AD - Kitasenri Maeda Clinic, 4-119, Furuedai, Suita, Osaka, 565-0874, Japan. FAU - Yokoyama, Hiroki AU - Yokoyama H AD - Jiyugaoka Medical Clinic, West 6, South 6-4-3, Obihiro, Hokkaido, 080-0016, Japan. FAU - Kosugi, Keisuke AU - Kosugi K AD - Kosugi Medical Clinic, 3-9, Tamatsukurimoto-cho, Tennoji-ku, Osaka, 543-0014, Japan. FAU - Ohtoshi, Kentaro AU - Ohtoshi K AD - Otoshi Medical Clinic, 8-47, Kakudacho, Osaka Kita-ku, Osaka, 530-0017, Japan. FAU - Hayashi, Isao AU - Hayashi I AD - Hayashi Clinic, 3-9-23, Koshienguchi, Nishinomiya, Hyogo, 663-8113, Japan. FAU - Sumitani, Satoru AU - Sumitani S AD - Center for Diabetes and Endocrinology, Nippon Life Hospital, 2-1-54 Enokojima, Nishi-ku, Osaka, 550-0006, Japan. FAU - Tsugawa, Mamiko AU - Tsugawa M AD - Department of Endocrinology and Metabolism, Ikeda Municipal Hospital, 3-1-18, Jonan, Ikeda, Osaka, 563-8510, Japan. FAU - Ryomoto, Kayoko AU - Ryomoto K AD - Center for Diabetes Mellitus, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8025, Japan. FAU - Taki, Hideki AU - Taki H AD - Diabetes Center, National Hospital Organization Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan. FAU - Nakamura, Tadashi AU - Nakamura T AD - Department of Internal Medicine, Kawasaki Hospital, 3-3-1, Higashiyamacho, Hyogo-ku, Kobe, Hyogo, 652-0042, Japan. FAU - Kawashima, Satoshi AU - Kawashima S AD - Kanda Naika Clinic, 5-21-3, Hannancho, Osaka Abeno-ku, Osaka, 545-0021, Japan. FAU - Sato, Yasunori AU - Sato Y AD - Department of Preventive Medicine and Public Health, Keio University School of Medicine, 45 Shinanomachi Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Watada, Hirotaka AU - Watada H AD - Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo, 113-8421, Japan. FAU - Shimomura, Iichiro AU - Shimomura I AD - Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan. CN - UTOPIA study investigators LA - eng PT - Journal Article DEP - 20210806 PL - United States TA - Diabetes Ther JT - Diabetes therapy : research, treatment and education of diabetes and related disorders JID - 101539025 PMC - PMC8385006 OTO - NOTNLM OT - Quality of life (QOL) OT - Sodium-glucose cotransporter 2 (SGLT2) inhibitor OT - Tofogliflozin OT - Type 2 diabetes mellitus FIR - Hayashi, I IR - Hayashi I FIR - Tsugawa, M IR - Tsugawa M FIR - Yokoyama, H IR - Yokoyama H FIR - Yoshii, H IR - Yoshii H FIR - Komiyama, K IR - Komiyama K FIR - Mita, T IR - Mita T FIR - Shimizu, T IR - Shimizu T FIR - Yamamoto, T IR - Yamamoto T FIR - Kawashima, S IR - Kawashima S FIR - Nakamura, T IR - Nakamura T FIR - Kamei, S IR - Kamei S FIR - Kinoshita, T IR - Kinoshita T FIR - Shimoda, M IR - Shimoda M FIR - Maeda, K IR - Maeda K FIR - Kosugi, K IR - Kosugi K FIR - Yoshii, H IR - Yoshii H FIR - Ishida, H IR - Ishida H FIR - Osonoi, T IR - Osonoi T FIR - Saito, M IR - Saito M FIR - Tamazawa, A IR - Tamazawa A FIR - Sumitani, S IR - Sumitani S FIR - Fujiki, N IR - Fujiki N FIR - Fujita, Y IR - Fujita Y FIR - Shimizu, S IR - Shimizu S FIR - Umayahara, Y IR - Umayahara Y FIR - Kato, K IR - Kato K FIR - Irie, Y IR - Irie Y FIR - Kataoka, R IR - Kataoka R FIR - Yasuda, T IR - Yasuda T FIR - Kiyohara, Y IR - Kiyohara Y FIR - Ohashi, M IR - Ohashi M FIR - Ryomoto, K IR - Ryomoto K FIR - Takahi, Y IR - Takahi Y FIR - Fujishima, Y IR - Fujishima Y FIR - Fujita, Y IR - Fujita Y FIR - Fukuhara, A IR - Fukuhara A FIR - Fukui, K IR - Fukui K FIR - Hosokawa, Y IR - Hosokawa Y FIR - Imagawa, A IR - Imagawa A FIR - Iwahashi, H IR - Iwahashi H FIR - Mukai, K IR - Mukai K FIR - Katakami, N IR - Katakami N FIR - Katsura, T IR - Katsura T FIR - Kawamori, D IR - Kawamori D FIR - Kimura, T IR - Kimura T FIR - Kobayashi, S IR - Kobayashi S FIR - Kozawa, J IR - Kozawa J FIR - Kubo, F IR - Kubo F FIR - Maeda, N IR - Maeda N FIR - Matsuoka, T IR - Matsuoka T FIR - Miyashita, K IR - Miyashita K FIR - Nakata, S IR - Nakata S FIR - Ninomiya, H IR - Ninomiya H FIR - Nishizawa, H IR - Nishizawa H FIR - Okuno, Y IR - Okuno Y FIR - Otsuki, M IR - Otsuki M FIR - Sakamoto, F IR - Sakamoto F FIR - Sasaki, S IR - Sasaki S FIR - Sato, I IR - Sato I FIR - Shimo, N IR - Shimo N FIR - Shimomura, I IR - Shimomura I FIR - Takahara, M IR - Takahara M FIR - Takano, T IR - Takano T FIR - Tokunaga, A IR - Tokunaga A FIR - Uno, S IR - Uno S FIR - Yamaoka, M IR - Yamaoka M FIR - Yoneda, S IR - Yoneda S FIR - Ohtoshi, K IR - Ohtoshi K FIR - Shiraiwa, T IR - Shiraiwa T FIR - Hajime, M IR - Hajime M FIR - Koikawa, K IR - Koikawa K FIR - Kuno, F IR - Kuno F FIR - Kurozumi, A IR - Kurozumi A FIR - Matsushita, K IR - Matsushita K FIR - Narisawa, M IR - Narisawa M FIR - Tanaka, K IR - Tanaka K FIR - Sugai, K IR - Sugai K FIR - Okada, Y IR - Okada Y FIR - Torimoto, K IR - Torimoto K EDAT- 2021/08/07 06:00 MHDA- 2021/08/07 06:01 PMCR- 2021/08/06 CRDT- 2021/08/06 12:30 PHST- 2021/05/21 00:00 [received] PHST- 2021/07/19 00:00 [accepted] PHST- 2021/08/07 06:00 [pubmed] PHST- 2021/08/07 06:01 [medline] PHST- 2021/08/06 12:30 [entrez] PHST- 2021/08/06 00:00 [pmc-release] AID - 10.1007/s13300-021-01125-8 [pii] AID - 1125 [pii] AID - 10.1007/s13300-021-01125-8 [doi] PST - ppublish SO - Diabetes Ther. 2021 Sep;12(9):2499-2515. doi: 10.1007/s13300-021-01125-8. Epub 2021 Aug 6.